EAB Member: Tarek A. Leil

Tarek A. Leil, PhD
Group Director – Quantitative Clinical Pharmacology
Clinical Pharmacology & Pharmacometrics
BRISTOL-MYERS SQUIBB

Room E.2140C
Rt. 206 & Province Line Road
Princeton, NJ 08540-4000
Tel: (609) 252-6502
Email: tarek.leil@bms.com

Tarek Leil is currently the head of the Quantitative Clinical Pharmacology (QCP) group within Clinical Pharmacology and Pharmacometrics (CP&P) at Bristol-Myers Squibb (BMS). The QCP group at BMS uses model based approaches, including quantitative systems pharmacology (QSP), physiologically based PK (PBPK), and model-based meta-analysis (MBMA), to integrate clinical and non-clinical data using models that summarize knowledge and generate actionable predictions. These predictions can be used to help with decision making in drug discovery and clinical development, to optimize the design of patient clinical trials, and to facilitate communications with regulatory authorities. Prior to joining BMS in 2011, Dr. Leil worked at Pfizer in the Department of Clinical Pharmacology. Dr. Leil and the QCP group have numerous recent publications and presentations demonstrating the utility of Pharmacometrics and Systems Pharmacology in Pharmaceutical R&D.

distancecell

Platform for Abused-Drugs and Neurological Diseases Association (PANDA)

PANDA is a portal for accessing the computational resources developed, disseminated and maintained by the CDAR Center, which comprises a significant expansion of the drug abuse research tools, as well as information toward establishing the link between molecular, cellular, and systemic aspects of drug abuse and associated disorders. Read more

distancecell

Cloud computing drug-abuse and neurobiological diseases domain-specific databases

These platforms are integrated with online structure search function and data analysis tools to facilitate data-sharing and information exchange among scientific research communities for target/off-target identification neurobiological drug abuse research. Read more

distancecell

Monoamine transporters: structure, intrinsic dynamics and allosteric regulation

Mary Cheng and Ivet Bahar published an invited review article in Nature Structural & Molecular Biology, addressing recent progress in the elucidation of the structural dynamics of monoamine transporters and their conformational landscape and transitions, as well as allosteric regulation mechanisms. Read more

distancecell

Targeting of dopamine transporter to filopodia requires an outward-facing conformation of the transporter

Using quantitative live-cell fluorescence microscopy (Sorkin lab; U PITT) and molecular modeling (Bahar lab), they investigated the effects of the DAT inhibitor cocaine and its fluorescent analog JHC1-64 on the plasma membrane distribution of wild-type DAT and two DAT mutants.

distancecell

A Time-Varying Group Sparse Additive Model for GWAS of Dynamic Complex Traits

Core C proposes a new approach, Linear Regression with Validated Association (LRVA) that discovers variants by utilizing the knowledge of known associations, making the variants with weaker signals easier to be identified. They have applied their method to Drug Abuse Disorders data set collected from CEDAR provided to them by Dr. Michael Vanyukov (PI of a FRP), and discovered nearly two dozen novel SNPs associated with drug abuse disorders. Literature search suggests that many of these SNPs reside in genes previously known to be involved with substance abuse. Read more